Medicare Enrolled
Dr. Eugenio Galindo, M.D.
Hematology & Oncology · McAllen, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Galindo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Galindo? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Galindo
Dr. Eugenio Galindo is a hematology & oncology in McAllen, TX, with 20 years in practice. Based on federal Medicare data, Dr. Galindo performed 27,001 Medicare services across 1,002 unique beneficiaries.
Between the years covered by Open Payments, Dr. Galindo received a total of $19,317 from 84 pharmaceutical and/or device companies across 1073 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Galindo is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 30% volume in TX$ $19,317 industry payments
Medicare Practice Summary
Medicare Utilization ↗27,001
Medicare services
Top 30% in TX for hematology & oncology
1,002
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,350 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 11,220 | $0 | $2 |
| Contrast dye for imaging (iodine-based) | 5,400 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 4,140 | $18 | $71 |
| Dexamethasone injection (steroid) | 2,008 | $0 | $1 |
| Blood draw (venipuncture) | 856 | $8 | $15 |
| Complete blood count (CBC) with differential | 819 | $8 | $30 |
| Flow cytometry, additional marker | 572 | $18 | $66 |
| Office visit, established patient (30-39 min) | 472 | $87 | $364 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 349 | $22 | $82 |
| Drug injection, under skin or into muscle | 216 | $10 | $40 |
| Administration of chemotherapy into vein, 1 hour or less | 199 | $97 | $368 |
| Administration of chemotherapy into vein, each additional hour | 181 | $21 | $80 |
| Office visit, established patient (20-29 min) | 95 | $67 | $257 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 93 | $23 | $96 |
| Injection, diphenhydramine hcl, up to 50 mg | 66 | $1 | $3 |
| Telephone medical discussion with physician, 21-30 minutes | 63 | $83 | $364 |
| Ct scan of abdomen and pelvis before and after contrast | 51 | $256 | $1,012 |
| Ct scan of chest before and after contrast | 48 | $153 | $580 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 33 | $45 | $180 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 33 | $16 | $58 |
| Complete ultrasound scan of 1 breast | 22 | $97 | $295 |
| Flow cytometry technique for dna or cell analysis, first marker | 22 | $56 | $165 |
| Telephone medical discussion with physician, 11-20 minutes | 22 | $64 | $257 |
| New patient office visit, complex (60-74 min) | 21 | $162 | $625 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
43.1% high complexity
46.0% medium
10.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$19,317
Total received (2018-2024)
Avg $2,760/year across 7 years
Top 21% in TX for hematology & oncology
84
Companies
1,073
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,986 (87.9%)
Other
Charitable contributions, space rental, and other categories
$1,583 (8.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$748 (3.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,268
2023$3,934
2022$3,314
2021$1,714
2020$887
2019$1,693
2018$3,509
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$2,018
E.R. Squibb & Sons, L.L.C.
$1,684
PFIZER INC.
$1,419
Janssen Biotech, Inc.
$1,352
US Oncology Corporate, Inc.
$1,312
Astellas Pharma US Inc
$1,126
AstraZeneca Pharmaceuticals LP
$1,006
Genentech USA, Inc.
$779
Merck Sharp & Dohme LLC
$619
Amgen Inc.
$611
GENZYME CORPORATION
$471
Merck Sharp & Dohme Corporation
$432
Gilead Sciences, Inc.
$404
Rigel Pharmaceuticals, Inc.
$330
Daiichi Sankyo Inc.
$300
NOVARTIS PHARMACEUTICALS CORPORATION
$299
PUMA BIOTECHNOLOGY, INC.
$266
Seagen Inc.
$263
Ipsen Biopharmaceuticals, Inc
$250
Takeda Pharmaceuticals U.S.A., Inc.
$237
Exelixis Inc.
$220
Lilly USA, LLC
$190
ABBVIE INC.
$175
Celgene Corporation
$158
Incyte Corporation
$158
Eisai Inc.
$148
Myriad Genetic Laboratories, Inc.
$144
Myovant Sciences Inc.
$144
Sumitomo Pharma America, Inc.
$139
Krystal Biotech Inc
$125
AbbVie, Inc.
$121
ARRAY BIOPHARMA INC
$118
Bayer HealthCare Pharmaceuticals Inc.
$113
Alexion Pharmaceuticals, Inc.
$108
EISAI INC.
$103
Karyopharm Therapeutics Inc.
$103
Bayer Healthcare Pharmaceuticals Inc.
$97
Regeneron Healthcare Solutions, Inc.
$93
JAZZ PHARMACEUTICALS INC.
$82
AVEO Pharmaceuticals, Inc.
$80
MorphoSys, US Inc.
$74
BeiGene USA, Inc.
$73
Puma Biotechnology, Inc.
$73
Coherus Biosciences Inc.
$71
Dova Pharmaceuticals
$68
Taiho Oncology, Inc.
$68
Nestle HealthCare Nutrition Inc.
$58
GlaxoSmithKline, LLC.
$52
TESARO, Inc.
$49
Clovis Oncology, Inc.
$48
Blueprint Medicines Corporation
$46
Spectrum Pharmaceuticals Inc.
$41
EMD Serono, Inc.
$40
Secura Bio, Inc.
$40
Fresenius Kabi USA, LLC
$40
Teva Pharmaceuticals USA, Inc.
$40
Octapharma USA, Inc.
$37
Verastem, Inc.
$36
Tempus AI, Inc
$34
Kite Pharma, Inc.
$33
Mirati Therapeutics, Inc.
$32
Pharmacyclics LLC, An AbbVie Company
$29
Kyowa Kirin, Inc.
$27
SOBI, INC
$26
SpringWorks Therapeutics, Inc.
$26
SECURA BIO, INC.
$25
Tactile Systems Technology Inc
$24
RECORDATI_RARE_DISEASES_INC.
$24
Seattle Genetics, Inc.
$24
Roche Diagnostics Corporation
$23
Amneal Pharmaceuticals LLC
$23
TerSera Therapeutics LLC
$23
TAIHO ONCOLOGY, INC.
$21
Helsinn Therapeutics (U.S.), Inc.
$20
Verity Pharmaceuticals Inc.
$20
Sun Pharmaceutical Industries Inc.
$19
Shire North American Group Inc
$17
AbbVie Inc.
$15
Sandoz Inc.
$15
PORTOLA PHARMACEUTICALS, INC.
$14
SANOFI-AVENTIS U.S. LLC
$14
Pharmacosmos Therapeutics Inc.
$13
Medtronic USA, Inc.
$12
R-Pharm US LLC
$11
Top 3 companies account for 26.5% of total payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALUNBRIG · ANDEXXA · AVASTIN · AYVAKIT · Alecensa · Avastin · BAVENCIO · BENDEKA · BOSULIF · BRACANALYSIS CDX · BRACAnalysis · BRAFTOVI · BRUKINSA · Balversa · Bavencio · CABLIVI · CALQUENCE · CD HORIZON · CHANTIX · COPIKTRA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DIS navify software · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · Enhertu · Erleada · FARESTON · FARYDAK · FOTIVDA · FRUZAQLA · Fabhalta · Farydak · Flexitouch Plus · Folotyn · GAZYVA · Gazyva · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Ixempra · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lupron · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NERLYNX · NINLARO · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · PADCEV · PIQRAY · POTELIGEO · PROMACTA · Perjeta · Pomalyst · REBLOZYL · RINVOQ · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SKYRIZI · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYLVANT · Somatuline Depot · Stimufend · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Trelstar · Trodelvy · Turalio · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VPRIV · VYJUVEK · Vectibix · Venclexta · XALKORI · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · YONSA · ZARXIO · ZEJULA · ZENPEP · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $72 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
11
Per 100K population
1.2
County median income
$52,281
Nearest hospital
SOUTH TEXAS HEALTH SYSTEM
3.4 mi
3.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Galindo is a mixed practice specialist, with above-average Medicare volume (top 30% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Galindo experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Galindo performed 11,220 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Galindo receive payments from pharmaceutical companies?
Yes. Dr. Galindo received a total of $19,317 from 84 companies across 1,073 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Galindo's costs compare to other hematology & oncologys in McAllen?
Dr. Galindo's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Galindo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in McAllen
Browse hematology & oncologys in McAllen ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology